Deimos Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Deimos Asset Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-5,000	Closed	-$368K	–	9
2016 Q2	$368K	Buy	+5,000	New	+$353K	0.16%	82

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Deimos Asset Management's BMY Position: Q3 2016 in Review

Deimos Asset Management sold out of Bristol-Myers Squibb (BMY) in Q3 2016, closing a stake of 5,000 shares — an estimated $368K sold.

Deimos Asset Management first reported a position in BMY in Q2 2016 and held it in 1 quarter. The position peaked at $368K in Q2 2016. 1,522 funds tracked by Wall St. Rank hold BMY as of Q3 2016.

Deimos Asset Management reported no remaining Bristol-Myers Squibb position as of Q3 2016 after selling out during the quarter.
Deimos Asset Management sold 5,000 Bristol-Myers Squibb shares in Q3 2016, an estimated $368K.
Deimos Asset Management first reported a position in Bristol-Myers Squibb in Q2 2016 and held it in 1 quarter.
Deimos Asset Management's Bristol-Myers Squibb position peaked at $368K in Q2 2016.
1,522 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2016.

Based on Deimos Asset Management's 13F filing for Q3 2016.